Abstract Number: 0664 • ACR Convergence 2021
Which Attributes Are the Most and Least Important to Patients When Considering Gout Flare Burden over Time? A Best-worst Scaling Choice Study
Background/Purpose: Several factors contribute to the patient experience of gout flares, including pain intensity, duration, frequency, and disability. It is unknown which of these factors…Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…Abstract Number: 0668 • ACR Convergence 2021
Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence
Background/Purpose: Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients’ perspectives and preferences. We aimed to investigate patients’ perspectives…Abstract Number: 0669 • ACR Convergence 2021
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…Abstract Number: 0672 • ACR Convergence 2021
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…Abstract Number: 0676 • ACR Convergence 2021
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting…Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…Abstract Number: 0680 • ACR Convergence 2021
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
Background/Purpose: Pegloticase is FDA-approved for uncontrolled gout and effectively lowers uric acid levels by conversion of circulating uric acid to allantoin, which is readily removed…Abstract Number: 0681 • ACR Convergence 2021
Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes
Background/Purpose: Gout is the most common inflammatory arthropathy worldwide. Despite having evidence-based guidelines, inconsistent management approaches remain a significant barrier to adequate treatment and prevention.…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 83
- Next Page »
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 83
- Next Page »
Didn't find what you were looking for? Try the Advanced Search »